Plain-English translation of NCT05870995 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment plan for a serious blood cancer called acute myeloid leukemia (AML) that has not responded to standard chemotherapy. The plan combines several chemotherapy drugs—including cladribine, cytarabine, etoposide, and venetoclax—followed by a reduced-intensity stem cell transplant. The goal is to reduce cancer relapse and side effects compared to older approaches.
Patients with hard-to-treat AML have very few good options and face high risks of cancer returning or serious complications from transplant. This trial aims to improve survival and quality of life by using a gentler conditioning approach before transplant while adding venetoclax, a newer medication that may help keep the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You would first receive intensive chemotherapy over about a week to reduce the cancer burden. After a short break, you would then receive a milder conditioning regimen (combination of chemotherapy and possibly radiation) to prepare your body for the stem cell transplant. On day zero, you would receive stem cells from your matched donor. Throughout the process, you would have frequent hospital visits and blood tests to monitor your response and manage side effects. The entire treatment and initial recovery period typically takes several weeks to months in the hospital.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China